RxDoctor Payments Data

Jaime Pugeda, MD

Cardiovascular Disease · Tacoma, WANPI 1639153281

Payments from drug & device makers

$1,206in general payments, 2019–2025

Across 38 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$290
  • Abiomed$234
  • Penumbra, Inc.$169
  • Shockwave Medical, Inc$100
  • Johnson & Johnson$75
  • Amgen$72
  • plus $267 from 9 others

What the payments were for

  • Food & beverage$1,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,206 in reported general payments places this provider in the 55th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$172,945
Medicare patients
822
Services billed
1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$303,549
XareltoRivaroxaban128$148,231
MultaqDronedarone Hcl22$34,065
Repatha SureclickEvolocumab27$28,807
EntrestoSacubitril/Valsartan14$17,145
Praluent PenAlirocumab17$15,197
BrilintaTicagrelor14$13,727
Metoprolol Succinate422$6,000
Atorvastatin Calcium334$3,236
Dabigatran EtexilateDabigatran Etexilate Mesylate18$3,056
Ranolazine ErRanolazine31$2,619
Ezetimibe89$1,834
Losartan Potassium127$1,544
Rosuvastatin Calcium120$1,441
Isosorbide Mononitrate ErIsosorbide Mononitrate97$1,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$75$148,231128 claims
NovartisEntresto$66$17,14514 claims
AstraZenecaBrilinta$67$13,72714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →